Significance of high-risk human papillomavirus DNA detection in women 50 years and older with squamous cell Papanicolaou test abnormalities

Archives of Pathology and Laboratory Medicine

Volumn 134, Issue 8, 2010, Pages 1130-1135

  Zhao, Chengquan ^a   Zhao, Shuping ^a,b   Heider, Amer ^a   Austin, R Marshall ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b QINGDAO UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ARTICLE; FEMALE; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MIDDLE AGED; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; PATHOLOGY; PRECANCER; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY;

CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PRECANCEROUS CONDITIONS; RETROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 77955346295     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Brooks, SE. Cervical cancer screening and the older woman: obstacles and opportunities. Cancer Pract. 1996;4(3):125-129.
2. Baquet B, Ringen K. Health policy: gaps in access, delivery, and utilization of the Pap smear in the United States. Milbank Mem Fund Q. 1987;65(suppl 2):332-347.
3. Bulten J, de Wilde PC, Boonstra H, Gemmink JH, Hanselaar AG. Proliferation in "atypical" atrophic smears. Gynecol Oncol. 2000;79(2):225-229.
4. Abati A, Jaffurs W, Wilder AM. Squamous atypia in the atrophic cervical vaginal smear: a new look at an old problem. Cancer Cytopathol. 1998;84(4):218-225.
5. Saminthen T, Lahoti C, Kannan V, Kline TS. Postmenopausal squamous cell atypias: a diagnostic challenge. Diagn Cytopathol. 1994;11(3):226-230.
6. Jovanovic AS, McLachlin CM, Shen L, Welch WR, Crum CP. Postmenopausal squamous atypia: a spectrum including "pseudo-koilocytosis." Mod Pathol. 1995;8(4):408-412.
7. Flynn K, Rimm DL. Diagnosis of "ASCUS" in women over age 50 is less likely to be associated with dysplasia. Diagn Cytopathol. 2001;24(2):132-136.
8. Ferenczy A, Gelfand MM, Franco E, Mansour N. Human papillomavirus infection in postmenopausal women with and without hormone therapy. Obstet Gynecol. 1997;90(1):7-11.
9. Burk RD, Kelly P, Feldman J, et al. Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. Sex Transm Dis. 1996;23(4):333-341.
10. Sawaya GF, Grady D, Kerlikowske K, et al. The positive predictive value of cervical smears in previously screened postmenopausal women: the heart and estrogen/progestin replacement study (HERS). Ann Intern Med. 2000;133(12):942-950.
11. Rader AE, Rose PG, Rodriguez M, Mansbacher S, Pitlik D, Abdul-Karim FW. Atypical squamous cells of undetermined significance in women over 55: comparison with the general population and implications for management. Acta Cytol. 1999;43(3):357-362.
12. Keating JT, Wang HH. Significance of a diagnosis of atypical squamous cells of undetermined significance for Papanicolaou smears in perimenopausal and postmenopausal women. Cancer Cytopathol. 2001;93(2):100-105.
13. Kaminski PF, Sorosky JI, Wheelock JB, Stevens CW. The significance of atypical cervical cytology in an older population. Obstet Gynecol. 1989;73(1):13-15.
14. Kaminski PF, Stevens CW, Wheelock JB. Squamous atypia on cytology: the influence of age. J Reprod Med. 1989;34(9):617-620.
15. Toplis PJ, Casemore V, Hallam, Charnock M. Evaluation of colposcopy in the postmenopausal woman. Br J Obstet Gynecol. 1986;93(8):843-851.
16. Shingleton HM, Partiridege EE, Asutin JM. The significance of age in the colposcopic evaluation of women with atypical Papanicolaou smears. Obstet Gynecol. 1977;49(1):61-64.
17. American Geriatric Society. Screening for cervical carcinoma in older women. J Am Ger Soc. 2001;49(5):655-657.
18. Nasca PC, Ellis N, Caputo TA, Saboda K, Metzger B. An epidemiologic study of Pap screening histories in women with invasive carcinomas of the uterine cervix. N Y State J Med. 1991;91(4):152-156.
19. Siegler EE. Cervical carcinoma in the aged. Am J Obstet Gynecol. 1969;103(8):1093-1097.
20. Mandelblatt J, Gopaul I, Wistreich M. Gynecological care of elderly women: another look at Papanicolaou smear testing. JAMA. 1986;256(3):367-371.
21. Wright TC, Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med. 2003;348(6):489-490.
22. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287(16):2114-2119.
23. US Census Bureau. American Community Survey (ACS) Web site. http://www.census.gov/acs/www/. Accessed October 14, 2009.
24. Zhao C, Austin RM. Human papillomavirus DNA detection in ThinPrep Pap test vials is independent of cytologic sampling of the transformation zone. Gynecol Oncol. 2007;107(2):231-235.
25. Zhao C, Austin RM. Adjunctive high-risk human papillomavirus DNA testing is a useful option for disease risk assessment in patients with negative Papanicolaou tests without an endocervical/transformation zone sample. Cancer Cytopathol. 2008;114(4):242-248.
26. Zhao C, Florea A, Onisko A, Austin RM. Histologic follow-up results in 662 patients with Pap test findings of atypical glandular cells: results from a large academic womens hospital laboratory employing sensitive screening methods. Gynecol Oncol. 2009;114(3):383-389.
27. Bandyopadhyay S, Austin RM, Dabbs D, Zhao C. Adjunctive human papillomavirus DNA testing is a useful option in some clinical settings for disease risk assessment and triage of females with ASC-H Papanicolaou test results. Arch Pathol Lab Med. 2008;132(12):1874-1881.
28. Armah H, Austin RM, Dabbs D, Zhao C. Follow-up findings for women with human papillomavirus-positive and atypical squamous cells of undetermined significance screening test results in a large women's hospital practice. Arch Pathol Lab Med. 2009;133(9):1426-1430.
29. Zhao C, Elishaev E, Yuan KH, Yu J, Austin RM. Very low human papillomavirus DNA prevalence in mature women with negative computer-imaged liquid-based Pap tests. Cancer. 2007;111(5):292-297.
30. Bansal M, Austin RM, Zhao C. High-risk HPV DNA detected in less than 2% of over 25, 000 cytology negative imaged liquid-based Pap test samples from women 30 and older. Gynecol Oncol. 2009;115(2):257-261.
31. Davey E, d'Assuncao J, Irwig L, et al. Accuracy of reading liquid based cytology slides using the ThinPrep Imager compared with conventional cytology: prospective study. BMJ. 2007;335(7609):31.
32. Castle PE, Lorincz AT, Scott DR, et al. Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer. J Clin Microbiol. 2003;41(9):4022-4030.
33. Saad R, Kanbour-Shakir A, Lu Erxiong, Modery J, Kanbour A. Cytomorphologic analysis and histological correlation of high grade squamous intraepithelial lesions in postmenopausal women. Diagn Cytopathol. 2006;34(7):467-471.
34. Saad R, Dabbs D, Kordunsky L, et al. Clinical significance of cytologic diagnosis of atypical squamous cells, cannot exclude high grade, in perimenopausal and postmenopausal women. Am J Clin Pathol. 2006;126(3):381-388.
35. Massad LS, Behbakht K, Collins YC, Cejtin HE. Histologic findings from the cervix among older women with abnormal cervical cytology. Gynecol Oncol. 2003;88(3):340-344.
36. Selvaggi SM. Atrophic vaginitis versus invasive squamous cell carcinoma on ThinPrep cytology: can the background be reliably distinguished? Diagn Cytopathol. 2002;27(6):362-364.
37. Keebler CM, Wied GL. The estrogen test: an aid in differential cytodiagnosis. Acta Cytol. 1974;18(6):482-493.
38. Piccoli R, Mandato VD, Lavitola G, et al. Atypical squamous cells and low squamous intraepithelial lesions in postmenopausal women: implications for management. Eur J Obstet Gynecol Reprod Biol. 2008;140(2):269-274.
39. Symmans F, Mechanic L, MacConnell P, Da Silva K, Stricker B, Nuovo GJ. Correlation of cervical cytology and human papillomavirus DNA detection in postmenopausal women. Int J Gynecol Pathol. 1992;11(3):204-209.
40. Smith EM, Johnson SR, Ritchie JM, et al. Persistent HPV infection in postmenopausal women. Int J Gynecol Obstet. 2004;87(2):131-137.
41. Huang AJ, Perez-Stable EJ, Kim SE, et al. Preferences for human papillomavirus testing with routine cervical cancer screening in diverse older women. J Gen Intern Med. 2008;23(9):1324-1329.
42. Irvin K, Montano D, Kasprzyk D, et al. Cervical cancer screening, abnormal cytology management, and counseling practices in the United States. Obstet Gynecol. 2006;108(2):397-409.
43. Ronco G, Cuzick J, Segnan N, et al. HPV triage for low grade (LSIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid-based cytology. Eur J Cancer. 2007;43(3):476-480.
44. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests (2006 American Society for Colposcopy and Cervical Pathology-Sponsored Consensus Conference). Am J Obstet Gynecol. 2007;197(4):346-355.
45. Davey DD, Greenspan D, Kurtycz D F I, Husain M, Austin RM. Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion: review of ancillary testing modalities and implications for follow-up. J Low Genit Tract Dis. 2010. In press.
46. Safeian F, Solomon D, Wacholder S, Schiffman M, Castle P. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance. Obstet Gynecol. 2007;109(6):1325-1331.
47. Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 2009;10(7):672-682.
48. Jeronimo J, Schiffman M. Colposcopy at a crossroads. Am J Obstet Gynecol. 2006;195(2):349-353.
49. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003;95(1):46-52.
50. Castle PE, Wacholder S, Lorincz AT, et al. A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst. 2002;94(18):1406-1414.
51. Castle PE, Wacholder S, Sherman ME, et al. Absolute risk of subsequent abnormal Pap among oncogenic human papillomavirus DNA-positive cytologically negative women. Cancer. 2002;95(10):2145-2151.
52. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97(14):1072-1079.
53. Tworek JA, Jones BA, Raab S, Clary KM, Walsh MK. The value of monitoring human papillomavirus DNA results for Papanicolaou tests diagnosed as atypical squamous cells of undetermined significance: a College of American Pathologists Q-Probes study of 68 institutions. Arch Pathol Lab Med. 2007;131(10):1525-1531.
54. Sherman ME, Schiffman M, Cox TJ. Effects of age and human papilloma viral load on colposcopy triage: data from the randomized atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study (ALTS). J Natl Cancer Inst. 2002;94(2):102-107.
55. Ronco G., Segnan N, Giorgi-Rossi P, et al., Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst. 2006;98(11):765-774.
56. Evans MF, Adamson CS, Papillo JL, St John TL, Leiman G, Cooper K. Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes. Cancer. 2006;106(5):1054-1064.
57. Solomon D, Schifffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001;93(4):293-299.
58. Cox JT, Schiffman M, Solomon D. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol. 2003;188(6):1406-1412.
59. Sherman ME, Castle PE, Solomon D. Cervical cytology of atypical squamous cells-cannot exclude high grade squamous intra-epithelial lesion (ASC-H): characteristics and histologic outcomes. Cancer. 2006;108(5):298-305.
60. Sherman ME, Solomon D, Schiffman M. Qualification of ASCUS: a comparison of equivocal LSIL and equivocal HSIL cervical cytology in the ASCUS/LSIL Triage Study. Am J Clin Pathol. 2001;116(3):386-394.
61. Austin RM, Oniśko A, Druzdzel M. The Pittsburgh Cervical Cancer Screening Model. Cancer Cytopathol. 2008;14(suppl): 345A.